Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease is increasing in prevalence. It can be subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). Five to twenty percent of cases progress from NAFL to NASH. Increased hepatic Th17 cells and IL-17 expression were observed in NASH mice and patients, respectively. We analyzed CD4+ effector T cells and regulatory T cells (Tregs) from peripheral blood and livers of NAFL and NASH patients. A total of 51 NAFL patients, 30 NASH patients, 31 nonalcoholic fatty liver disease patients (without histology), and 43 healthy controls were included. FACS analysis was performed on PBMCs and intrahepatic lymphocytes. Compared with healthy controls, a lower frequency of resting Tregs (rTregs; CD4+CD45RA+CD25++) and higher frequencies of IFN-γ+ and/or IL-4+ cells were detected among CD4+ T cells of peripheral blood in NASH, and to a lesser degree in NAFL. In hepatic tissue, NAFL to NASH progression was marked by an increase in IL-17+ cells among intrahepatic CD4+ T cells. To define immunological parameters in peripheral blood to distinguish NAFL from NASH, we calculated different ratios. Th17/rTreg and Th2/rTreg ratios were significantly increased in NASH versus NAFL. The relevance of our findings for NASH pathogenesis was highlighted by the normalization of all of the changes 1 y after bariatric surgery. In conclusion, our data indicate that NAFL patients show changes in their immune cell profile compared with healthy controls. NAFL to NASH progression is marked by an increased frequency of IL-17+ cells among intrahepatic CD4+ T cells and higher Th17/rTreg and Th2/rTreg ratios in peripheral blood.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with similar trends in CCL5+HOPX+ TH1 cells in both compartments and RTKN2+CCR7lo memory Treg cells in the liver (Fig. 5g)”
In the citing paper
“we observed a positive correlation of CD45RO+SELLhi CD4+ TCM cells and KLRB1+RORC+ TH17 cells in both liver and blood with fibrosis”
In the citing paper
“We found a marked increase in proinflammatory TH1 cell and TH17 cell frequency and function with MASH in the liver and peripheral blood, consistent with previous reports32,33, alongside an increase in RTKN2+CCR7lo memory Treg cells”
In the citing paper
“CD4 + T H 17 cells and CD8 + T cells have been shown to mediate NASH-associated liver fibrosis in both mice and humans (5-9).”
From NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis (2023) · cites this paper as [8]
Citations
Cites
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605 · cited 1×
“whereas TGF-b alone induces Tregs instead of Th17 cells (6, 7).”
BackgroundAngulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203 · cited 1×
“3 (13) Elevated alkaline phosphatase (% [n]) 9.”
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
The utility of radiological imaging in nonalcoholic fatty liver disease
Saadeh, S., Younossi, Z. M., Remer, E. M., Gramlich, T., Ong, J. P., Hurley, M., Mullen, K. D., Cooper, J. N., & Sheridan, M. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.35354 · Cited by 2,110 · cited 1×
“Eight-one patients had histology-proven NAFL or NASH, and 31 patients were diagnosed with NAFLD by typical ultrasound findings, as described by sonographic NASH score (11).”
MethodThe Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation
Ouyang, W., Kolls, J. K., & Zheng, Y. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.004 · Cited by 1,700 · cited 4×
“The inflammatory process underlying NASH is characterized by elevated expression of inflammatory cytokines, such as TNF-a and IL-6.”
InfluentialBrunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251
Standardizing immunophenotyping for the Human Immunology Project
Maecker, H. T., McCoy, J. P., & Nussenblatt, R. (2012) · Nature Reviews Immunology · doi:10.1038/nri3158 · Cited by 1,176 · cited 1×
“To determine whether the liver-infiltrating T cells are recently activated cells, we stained for HLA-DR expression (19).”
BackgroundLi, M. O., Sanjabi, S., & Flavell, R. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.07.011 · Cited by 805
The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease
Gadd, V. L., Skoien, R., Powell, E. E., Fagan, K. J., Winterford, C., Horsfall, L., Irvine, K., & Clouston, A. D. (2014) · Hepatology · doi:10.1002/hep.26937 · Cited by 452 · cited 1×
“Cells expressing several T cell markers were recently identified by immunostaining in NAFLD liver biopsy sections (20).”
BackgroundThe interleukin-17 pathway is involved in human alcoholic liver disease # †
Lemmers, A., Moreno, C., Gustot, T., Maréchal, R., Degré, D., Demetter, P., de Nadai, P., Geerts, A., Quertinmont, E., Vercruysse, V., et al. (2009) · Hepatology · doi:10.1002/hep.22680 · Cited by 394
Cited by
Items 101–200 of 302
Advances in T Cells Based on Inflammation in Metabolic Diseases
Yu, W., Li, C., Zhang, D., Li, Z., Xia, P., Liu, X., Cai, X., Yang, P., Ling, J., Zhang, J., et al. (2022) · Cells · doi:10.3390/cells11223554 · Cited by 44
Zheng, K. I., Liu, W., Pan, X.-Y., Ma, H., Zhu, P., Wu, X., Targher, G., Byrne, C. D., Wang, X., Chen, Y., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001174 · Cited by 41
Intrahepatic TH17/TReg Cells in Homeostasis and Disease—It’s All About the Balance
Drescher, H. K., Bartsch, L. M., Weiskirchen, S., & Weiskirchen, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.588436 · Cited by 47
Abdelnabi, M. N., Hassan, G. S., & Shoukry, N. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437046 · Cited by 46
Chang, E., Kim, D., Yang, H., Lee, D. H., Bae, S. H., & Park, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206152 · Cited by 39
RORγ Structural Plasticity and Druggability
Huang, M. S., Bolin, S., Miller, H., & Ng, H. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155329 · Cited by 42
“For nonalcoholic fatty liver disease, increased hepatic Th17 cells, RORγt and IL-17 expression are observed in the progression from one subtype nonalcoholic fatty liver disease to the other subtype nonalcoholic steatohepatitis [6,7].”
BackgroundAtif, M., Warner, S., & Oo, Y. H. (2018) · Hepatology International · doi:10.1007/s12072-018-9882-x · Cited by 40
Gut dysbiosis and metabolic diseases
Bandopadhyay, P., & Ganguly, D. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.06.031 · Cited by 45
Kabbani, M., Michailidis, E., Steensels, S., Fulmer, C. G., Luna, J. M., Pen, J. L., Tardelli, M., Razooky, B. S., Ricardo-Lax, I., Zou, C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111321 · Cited by 38
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Petagine, L., Zariwala, M. G., & Patel, V. B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i32.4831 · Cited by 44
Perivascular stromal cells: Directors of tissue immune niches
Sbierski‐Kind, J., Mroz, N. M., & Molofsky, A. B. (2021) · Immunological Reviews · doi:10.1111/imr.12984 · Cited by 39
Shen, T., Chen, X., Li, Y., Tang, X., Jiang, X., Yu, C., Zheng, Y., Guo, H., & Ling, W. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.01.027 · Cited by 36
Wang, H., Tsung, A., Mishra, L., & Huang, H. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105031 · Cited by 41
“29 Type 17 T helper (Th17) cells, a pro-in fl ammatory subtype of CD4 + T cells mainly secreting interleukin 17A (IL-17A), have shown a pronounced accumulation in the liver of patients with MASH.”
BackgroundBiagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 37
“154 Interestingly, the progression from NAFLD to NASH is associated with a robust accumulation of Th17 cells in the liver, and this change normalizes one year after bariatric surgery in conjunction with the alleviation of NASH features.”
Gau, S., Huang, K., Lee, C., Kuan, Y., Tsai, T., & Lee, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840106 · Cited by 40
“0 (for NAFLD) and K76 (for NASH) were also applied by population-based studies (52, 53).”
BackgroundOlveira, A., Augustín, S., Benlloch, S., Ampuero, J., Suárez‐Pérez, J. A., Armesto, S., Vilarrasa, E., Belinchón, I., Herranz, P., Crespo, J., et al. (2023) · Life · doi:10.3390/life13020419 · Cited by 44
“A prospective study of 112 patients with MAFLD found that progression to NASH was correlated with the intrahepatic increase in TH17 lymphocytes, and a significant increase in the TH17/Treg ratio in peripheral blood [73].”
BackgroundFunctional heterogeneity of CD4+ T cells in liver inflammation
Muscate, F., Woestemeier, A., & Gagliani, N. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00881-w · Cited by 32
Gut microbiota, immunity, and bile acid metabolism: decoding metabolic disease interactions
Zhao, Q., Wu, J., Ding, Y., Pang, Y., & Jiang, C. (2023) · Life Metabolism · doi:10.1093/lifemeta/load032 · Cited by 35
Immune regulation and therapeutic application of T regulatory cells in liver diseases
Ajith, A., Merimi, M., Arki, M. K., Hossein‐Khannazer, N., Najar, M., Vosough, M., Sokal, E. M., & Najimi, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371089 · Cited by 37
The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC
Wu, Q., Yang, Y., Lin, S., Geller, D. A., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569915 · Cited by 32
Nonalcoholic fatty liver disease and colorectal cancer: Correlation and missing links
Chakraborty, D., & Wang, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118507 · Cited by 36
“In obese individuals with NAFLD, an increase in Th17/Treg is observed, which is associated with a more rapid progression from NAFLD to NASH as compared to lean individuals [77].”
BackgroundMirshahi, F., Aqbi, H. F., Isbell, M., Manjili, S. H., Guo, C., Saneshaw, M., Bandyopadhyay, D., Dozmorov, M. G., Khosla, A., Wack, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110454 · Cited by 32
Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies
Jahn, D., Rau, M., Wohlfahrt, J., Hermanns, H. M., & Geier, A. (2016) · Digestive Diseases · doi:10.1159/000444547 · Cited by 34
Self-citationRegulatory T-Cell Therapy in Liver Transplantation and Chronic Liver Disease
Hann, A., Oo, Y. H., & Perera, M. T. P. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719954 · Cited by 32
“If Tregs are considered the suppressive T-cell lineage, T-helper 17 (Th17) and T-helper 1 (Th1) cells have the opposing role of being pro-inflammatory or regenerative due to their IL-17, IL-22, IFN-g, and TNF-a secretion (21).”
BackgroundPathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 40
Carrascosa, J. M., Puig, L., Romero, I. B., Salgado‐Boquete, L., del Alcázar, E., Lencina, J. J. A., Moreno-Ramírez, D., & de la Cueva, P. (2022) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2022.01.024 · Cited by 36
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 33
Marqués, P., Francisco, V., Martínez‐Arenas, L., Carvalho‐Gomes, Â., Domingo, E., Piqueras, L., Berenguer, M., & Sanz, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032313 · Cited by 32
“Nevertheless, since the vast majority of the scientific literature included in this review was still based on NAFLD diagnostic criteria, the terms NAFLD, NAFL and NASH were used herein.”
BackgroundResultInfluentialLiu, Y., Hao, Y., Boeckmans, J., Rodrigues, R. M., & He, Y. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108353 · Cited by 31
Van Herck, M. A., Vonghia, L., Kwanten, W. J., Vanwolleghem, T., Ebo, D. G., Michielsen, P. P., De Man, J. G., Gama, L., De Winter, B. Y., & Francque, S. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01711 · Cited by 30
Vachliotis, I. D., & Pοlyzos, S. A. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00657-5 · Cited by 33
“In NAFLD patients, increased frequency of intrahepatic IL-17 + cells, along with an increased Th17/Treg ratio in both peripheral blood and liver tissues, have been associated with the progression from hepatic steatosis to NASH [70 ].”
Yang, X., Li, C., Ng, T., Liu, J., Liu, H., Zhang, W., Xiao, F., Li, X., Lo, C. M., Lu, L., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ma0520-716r · Cited by 33
Riaz, F., Wei, P. Y., & Pan, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.949603 · Cited by 32
“A recent clinical study showed the low population of resting Tregs in the peripheral blood of NASH patients and an increase in intrahepatic Th17 cells (Rau et al., 2016), suggesting that higher Th17/rTreg is engaged in NAFL to NASH progression.”
BackgroundCrucial role of T cells in NAFLD-related disease: A review and prospect
Mao, T., Yang, R. X., Luo, Y., & He, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1051076 · Cited by 33
“Th2 cells in peripheral blood of NAFLD patients are increased compared with healthy controls (49), while no differences in number of Th2 cells in peripheral blood or the liver have been observed between NASH patients and NAFLD patients or controls (50, 61).”
BackgroundInfluentialMulticytokine-producing CD4+ T cells characterize the livers of patients with NASH
Woestemeier, A., Scognamiglio, P., Zhao, Y., Wagner, J., Muscate, F., Casar, C., Siracusa, F., Cortesi, F., Agalioti, T., Müller, S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.153831 · Cited by 28
“Discussion By providing an unsupervised analysis, our study shows for the first time to our knowledge that the progressive inflammatory development behind the transition from NAFLD to NASH is not associated with only classical CD4+ Th cell subsets, as previously suggested (6, 30, 35, 36), but rather with a larger spec…”
BackgroundMethodMechanisms of liver fibrosis in metabolic syndrome
Mehal, W. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100015 · Cited by 28
Çebi, M., & Yilmaz, Y. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1445634 · Cited by 30
Metabolic reprogramming of immune cells in MASH
Ma, C., Wang, S., Dong, B., & Tian, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001371 · Cited by 35
The emerging role of tissue regulatory T cells in tissue repair and regeneration
Raheem, A., Khan, I., Ahmad, I., Wajid, A., Alshahrani, M. Y., Alzahrani, F. M., Alzahrani, K. J., Qadeer, A., Liao, I., & Chen, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1640113 · Cited by 29
Han, J., & Zhang, X. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.653293 · Cited by 31
“In the early stage of NAFLD, bacterial endotoxin, free fatty acid (FFA), cholesterol and many other substances in the body can activate the complement system through danger associated molecular patterns (DAMPs) or pathogen associated molecular pattern (PAMPs) (5, 6).”
BackgroundLiu, J., Ding, M., Bai, J., Luo, R., Liu, R., Qu, J., & Li, X. (2023) · iMeta · doi:10.1002/imt2.76 · Cited by 25
“Interestingly, after bariatric surgery, the ratio of Th17/rTreg cells in MAFLD patients was significantly altered, as evidenced by the decreased production of Th17 cells and IL ‐ 17 as well as the increased production of Treg cells in the peripheral blood [101].”
BackgroundRomeo, M., Silvestrin, A., Senese, G., Nardo, F. D., Napolitano, C., Vaia, P., Coppola, A., Federico, P., Dallio, M., & Federico, A. (2025) · Biomedicines · doi:10.3390/biomedicines13082004 · Cited by 32
“In MASLD, while data on the total hepatic CD4 + T cell numbers are conflicting [96], there is evidence of a Th1/Th17 shift and increased IFN γ and IL-17A levels, promoting inflammation and fibrosis [96–98].”
Novel Immune Subsets and Related Cytokines: Emerging Players in the Progression of Liver Fibrosis
Wan, M., Han, J., Ding, L., Hu, F., & Gao, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.604894 · Cited by 30
“Considering that insulin resistance promotes the development from simple fatty liver to NASH and is a common risk factor for NAFLD (57, 58), it is reasonable to assume that VAT Tregs participate in the regulation of NASH development.”
BackgroundInfluentialPeripheral immune cells in NAFLD patients: A spyhole to disease progression
Lin, S., & Fan, J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103768 · Cited by 30
Ickrath, P., Kleinsasser, N. H., Ding, X., Ginzkey, C., Beyersdorf, N., Hagen, R., Kerkau, T., & Hackenberg, S. (2017) · Allergy & Rhinology · doi:10.2500/ar.2017.8.0214 · Cited by 26
Self-citationCheng, C., Zhang, Q., Li, Y., Jiang, J., Xie, L., Shen, H., Wu, D., Zhang, H., Zhang, H., Wang, X., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.09.010 · Cited by 29
“Together, these data demonstrated that in contrast to the protective function of NK cells, liver ILC1 played an important role in the pathogenesis of ethanol-induced steatohepatitis through the release of IL17A.”
ResultInfluentialWu, J., Zheng, L., Mo, J., Yao, X., Fan, C., & Bao, Y. (2020) · BioMed Research International · doi:10.1155/2020/9329427 · Cited by 24
“It is reported that in the formation of nonalcoholic fatty liver, Th17 cells were increased in the liver, and the Th17/resting Treg ratio was elevated both in the peripheral blood and the liver [27].”
BackgroundZhang, W., Lu, W., Jiao, Y., Li, T., Wang, H., & Wan, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06490-7 · Cited by 27
“The liver tissue from MASH patients contained higher levels of activated Tregs, suggesting an active role of these cells in suppressing chronic inflammation and tissue damage [66].”
Kado, A., Tsutsumi, T., Enooku, K., Fujinaga, H., Ikeuchi, K., Okushin, K., Moriya, K., Yotsuyanagi, H., & Koike, K. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01565-x · Cited by 23
Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis
Kartasheva-Ebertz, D., Pol, S., & Lagaye, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691073 · Cited by 25
“Th17/Treg ratio was significantly higher in NASH patients, and the Tregs count, on the contrary, was much lower (108).”
BackgroundAmersfoort, J., Douna, H., Schaftenaar, F. H., Foks, A. C., Kröner, M. J., van Santbrink, P. J., van Puijvelde, G. H. M., Bot, I., & Kuiper, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02937 · Cited by 24
“Patients with hepatic steatosis have increased intrahepatic IL-17 expressing CD4 T cells while in the blood, more IFNy secreting CD4 T cells are detected as compared to healthy controls (36).”
BackgroundThe Nr4a family regulates intrahepatic Treg proliferation and liver fibrosis in MASLD models
Aki, D., Hayakawa, T., Srirat, T., Shichino, S., Ito, M., Saitoh, S.-I., Mise-Omata, S., & Yoshimura, A. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175305 · Cited by 22
“Metabolic dysfunction-associated steatotic liver disease (MASLD) is a liver disorder characterized by the accumulation of fat in the liver without significant alcoholic intake, and its prevalence is estimated to be around 25% (1).”
InfluentialAdvancements in MAFLD Modeling with Human Cell and Organoid Models
Wang, S.-X., Yan, J.-S., & Chan, Y.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911850 · Cited by 22
“Histological analysis of NASH patient tissues also identified changes in the T cell population, including increased T helper 17 (TH17) cells and decreased regulatory T (Treg) cells [133].”
BackgroundZhang, H., Xiong, Y., Yang, C., Zhan, Q., Fu, Y., Luo, H., & Luo, H. (2020) · Journal of Viral Hepatitis · doi:10.1111/jvh.13352 · Cited by 22
Park, E., Jeong, J., Won, S., Sharma, S. P., Gebru, Y. A., Ganesan, R., Gupta, H., Suk, K. T., & Kim, D. J. (2021) · Cells · doi:10.3390/cells10102634 · Cited by 24
“In addition to the elevated blood ethanol levels, children with NASH showed an increase in ethanolproducing bacteria in their gut microbiota [16].”
BackgroundInfluentialThe role of Th17 cells in endocrine organs: Involvement of the gut, adipose tissue, liver and bone
Zi, C., Wang, D., Gao, Y., & He, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1104943 · Cited by 29
“The increased expression of hepatic Th17 cells and IL-17 were detected in NASH mice and patients, separately (131).”
BackgroundAarts, S. A. B. M., Reiche, M. E., den Toom, M., Gijbels, M. J., Beckers, L., Gerdes, N., & Lutgens, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-50976-6 · Cited by 24
Fatty acid-driven modifications in T-cell profiles in non-alcoholic fatty liver disease patients
Seike, T., Mizukoshi, E., Yamada, K., Okada, H., Kitahara, M., Yamashita, T., Arai, K., Terashima, T., Iida, N., Fushimi, K., et al. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01679-7 · Cited by 24
“NAFLD patients is consistent with previous studies reporting that Th17 cells are involved in the progression from non-alcoholic fatty liver (NAFL) to NASH [21] (Supplementary Fig.”
ResultWang, Y., Tian, L., Fabi, J. P., & de Vos, P. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107539 · Cited by 28
Th17 cells in the liver: balancing autoimmunity and pathogen defense
Taniki, N., Nakamoto, N., Chu, P., Ichikawa, M., Teratani, T., & Kanai∥, T. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00917-9 · Cited by 24
Mesenchymal stem cells-based therapy in liver diseases
Han, H., Jin, W., & Li, X. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00088-x · Cited by 25
Weiskirchen, R., & Tacke, F. (2016) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2016.09.10 · Cited by 20
“Interestingly, a recent study that enrolled 112 patients suffering from different fatassociated hepatic diseases and 43 healthy controls reported that NAFLD patients show that the progression of NAFLD to NASH is marked by an increased frequency of IL-17 positive cells among intrahepatic CD4 T lymphocytes (26).”
BackgroundKuo, J., Serrano, S. S., Grönberg, A., Massoumi, R., Hansson, M. J., & Gallay, P. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01129 · Cited by 20
Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells
Koda, Y., Nakamoto, N., & Kanai∥, T. (2022) · Seminars in Liver Disease · doi:10.1055/a-1957-6384 · Cited by 21
van der Zande, H. J. P., Brombacher, E. C., Lambooij, J. M., Pelgrom, L. R., Zawistowska‐Deniziak, A., Patente, T. A., Heieis, G. A., Otto, F., Ozir‐Fazalalikhan, A., Yazdanbakhsh, M., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.157948 · Cited by 21
Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion
Zhang, C., & Yang, M. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.789859 · Cited by 19
“Th17 Cells In the progression of NAFLD to NASH, hepatic IL-17CD4 T (Th17) cells were significantly increased, and the ratio of Th17 or Th2 to CD4CD45RACD25 resting Tregs (rTregs) was elevated in peripheral blood (37).”
BackgroundFeng, D. (2020) · Liver Research · doi:10.1016/j.livres.2020.02.003 · Cited by 18
Role of regulatory T cells in inflammatory liver diseases
Yang, L., & Zheng, S. G. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103806 · Cited by 19
Waller, K., Saihi, H., Li, W., Brindley, J. H., Jong, A. D., Syn, W., Bessant, C., & Alazawi, W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0205 · Cited by 19
“8 Consistent with this, we found that Th1 cells and CD8-expressing cytotoxic T cells were increased in patients with steatosis, and these remained elevated in NASH and fibrosis patients, albeit with lower levels of key phosphorylated signalling mediators, which may reflect an exhausted phenotype in…”
ResultVitamin D/vitamin D receptor pathway in non-alcoholic fatty liver disease
Liu, J., Song, Y., Ye, W., & Hong, H. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2274099 · Cited by 21
“…and Th17 cell subsets is enhanced [71] and the ratio of Th17 to Tregs becomes imbalanced [74] in case of NAFLD, and the cytokines produced by these cells (such as IFNγ, and IL-17) trigger local hepatic inflammation and destroy immune homeostasis, exacerbating the progression of NAFL to NASH [75].”
BackgroundInflammatory Network of Liver Fibrosis and How It Can Be Targeted Therapeutically
Lowe, K., Tanase, C. E., Maghami, S., Fisher, L. E., & Ghaemmaghami, A. M. (2023) · Immuno · doi:10.3390/immuno3040023 · Cited by 22
Tzeng, H., & Lee, W. (2024) · Nutrients · doi:10.3390/nu16091388 · Cited by 20
“Moreover, in patients with NASH, the frequency of interferon (IFN)- γ -expressing CD4 + T cells is higher than that observed in healthy individuals [23].”
BackgroundNonalcoholic fatty liver disease and cardiovascular disease phenotypes
Bisaccia, G., Ricci, F., Mantini, C., Tana, C., Romani, G. L., Schiavone, C., & Gallina, S. (2020) · SAGE Open Medicine · doi:10.1177/2050312120933804 · Cited by 21
Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries
Sisto, M., & Lisi, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175699 · Cited by 21
“Subsequently, active STAT3 up-regulates the expression of the transcription factor RORγt, which is critical for IL-17 production [26].”
BackgroundInfluentialSbierski‐Kind, J., Kath, J., Brachs, S., Streitz, M., von Herrath, M. G., Kühl, A. A., Schmidt‐Bleek, K., Mai, K., Spranger, J., & Volk, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01069 · Cited by 23
“However, recent data suggest the involvement of adaptive immunity, represented particularly by T cells (17, 18), showing the complexity of obesity-associated intratissue inflammation (19).”
BackgroundThe PD-1/PD-L1 Axis in the Biology of MASLD
Pipitone, R. M., Lupo, G., Zito, R., Javed, A., Petta, S., Pennisi, G., & Grimaudo, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073671 · Cited by 22
“not clear if it extrahepatic factors (Figure 3) [67].”
InfluentialLactobacillus pentosus strain S-PT84 improves steatohepatitis by maintaining gut permeability
Sakai, Y., Arie, H., Ni, Y., Zhuge, F., Xu, L., Chen, G., Nagata, N., Suzuki, T., Kaneko, S., Ota, T., et al. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0105 · Cited by 17
The role of glycolysis in MASLD development: Pathogenesis and therapeutic strategies
Shang, Y., Sun, Q., Xin, X., Wang, Z., Gao, S., Lin, R., Hu, Y., Wang, X., & Feng, Q. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107990 · Cited by 18
Arvanitakis, K., Papadakos, S. P., Lekakis, V., Koufakis, T., Lempesis, I. G., Papantoniou, E., Kalopitas, G., Georgakopoulou, V., Stergiou, I. Ε., Theocharis, S. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914704 · Cited by 16
“…cellular populations such as Th17 CD4+ and CD8+ T cells, NK cells, B cells, M1 macrophages and neutrophils in omentum [68], and CD14+ Kupffer cells [102], MOP+ neutrophils [103], TNF+ dendritic cells [104], TH17 CD4+ T cells [105], CD8+ T cells [106], and CD3+CD56+ V α 24+ iNKT cells [107].”
BackgroundLiver damage promotes pro‐inflammatory T‐cell responses against apolipoprotein B‐100
Plochg, B. F. J., Englert, H., Rangaswamy, C., Konrath, S., Malle, M., Lampalzer, S., Beisel, C., Wollin, S., Frye, M., Aberle, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13434 · Cited by 16
Endothelial c‐Myc knockout enhances diet‐induced liver inflammation and fibrosis
Qi, Y., Qadir, M. M. F., Hastreiter, A. A., Fock, R. A., Machi, J. F., Morales, A. A., Wang, Y., Meng, Z., & Rodrigues, C. O. (2021) · The FASEB Journal · doi:10.1096/fj.202101086r · Cited by 19
Tao, S., Lei, Y., Tan, Y.-M., Yang, Y., & Xie, W. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1476419 · Cited by 18
The many pathways driving liver inflammation in MASH
Tilg, H., Adolph, T. E., Romeo, S., & Loomba, R. S. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.02.018 · Cited by 20
Immune Checkpoints and the Immunology of Liver Fibrosis
Tsomidis, I., Voumvouraki, A., & Kouroumalis, E. (2025) · Livers · doi:10.3390/livers5010005 · Cited by 16
Yang, M. J., Khoukaz, L., Qi, X., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2021) · Biomedicines · doi:10.3390/biomedicines9121893 · Cited by 18
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease
Yamauchi, Y., Sharpe, L. J., & Brown, A. J. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01168-3 · Cited by 17
Negi, C. K., Khan, S., Dirven, H. A. A. M., Bajard, L., & Bláha, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084282 · Cited by 14
Takezaki, D., Morizane, S., Ikeda, K., Iseki, M., Sakamoto, Y., Kawakami, Y., Hashiguchi, T., Shirakata, Y., Nishina, S., & Mukai, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1214623 · Cited by 15
“In terms of mechanism, the involvement of intrahepatic Th17 cells and serum IL-6, IL-17, and IL-23 has been demonstrated in a murine NASH model and human patients with NAFLD (33, 34).”
BackgroundThe double roles of T cell-mediated immune response in the progression of MASLD
Li, Z., Wang, S., Xu, Q., Su, X., Wang, Y., Wang, L., & Zhang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116333 · Cited by 19
Advances in Liver Transplantation: where are we in the pursuit of transplantation tolerance?
Safinia, N., Vaikunthanathan, T., Lechler, R. I., Fueyo, A. S., & Lombardi, G. (2021) · European Journal of Immunology · doi:10.1002/eji.202048875 · Cited by 14
Chronic low-grade inflammation is involved in TLR4 knockout-induced spontaneous obesity in aged mice
Zhou, Z.-Y., Deng, Y., Wen, Y., Cheng, Y., Li, K., & Chen, H.-P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112637 · Cited by 15
Li, G., Li, H., & Chen, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161269 · Cited by 13
“Moreover, IFN-g-expressing CD4+ T cells were enriched in NASH, and methionine/choline deficient (MCD) diet feeding induced milder steatohepatitis and decreased inflammatory macrophage infiltration in mice deficient in IFN-g compared to the control mice (37, 38).”
BackgroundFrom NAFLD to HCC: Is IL‐17 the crucial link?
Hatting, M., & Tacke, F. (2016) · Hepatology · doi:10.1002/hep.28934 · Cited by 14
“The progression from steatosis to steatohepatitis in human patients is associated with an increase of hepatic IL-17(1) cells from the CD4 cell population.((7)) Moreover, IL-17 signaling was found to promote liver damage in several models of liver disease((8)) as well as in obesity-related animal models of NAFLD.”
BackgroundLamadrid, P., Alonso‐Peña, M., Segundo, D. S., Arias, M., Crespo, J., & López‐Hoyos, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651728 · Cited by 14
Jin, J., Cheng, K., Chen, M., Liang, H., & Zhang, W. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.117394 · Cited by 16
“Th17 cells are also demonstrated to be increased [119, 120].”
T cell trafficking in human chronic inflammatory diseases
Giovenzana, A., Codazzi, V., Pandolfo, M., & Petrelli, A. (2024) · iScience · doi:10.1016/j.isci.2024.110528 · Cited by 13
Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis
Chung, K. W., Cho, Y. E., Kim, S.-J., & Hwang, S. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01379-1 · Cited by 11
Sun, R., Xiang, Z., & Wu, B. (2022) · Portal hypertension & cirrhosis · doi:10.1002/poh2.11 · Cited by 14
Costante, F., Airola, C., Santopaolo, F., Gasbarrini, A., Pompili, M., & Ponziani, F. R. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i9.1622 · Cited by 14
Immune activation induced by dysregulated lipid metabolism in the pathogenesis of type 2 diabetes
Yang, H., Yu, W., Mao, Q., & Zhao, L. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.114395 · Cited by 11
Metadata
- Authors
- Rau, M., Schilling, A.-K., Meertens, J., Hering, I., Weiss, J., Jurowich, C., Kudlich, T., Hermanns, H. M., Bantel, H., Beyersdorf, N., & Geier, A.
- Affiliations
- Universitätsklinikum Würzburg (DE)
- Medizinische Hochschule Hannover (DE)
- University of Würzburg (DE)
- Corresponding author
- Rau, Monika
- Meertens, Jan
- Hering, Ilona
- Weiss, Johannes
- Kudlich, Theodor
- Geier, Andreas
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-01
- Volume
- 196
- Issue
- 1
- Pages
- 97-105
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2219561900
- Cited by
- 302
- References
- 30
- Citations by year
- 2026: 14 · 2025: 54 · 2024: 33 · 2023: 34 · 2022: 40 · 2021: 46 · 2020: 29 · 2019: 13 · 2018: 18 · 2017: 11 · 2016: 9
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, disease progression, Th17 cells, regulatory T cells, IL-17, CD4+ T cells, Th1/Th2 balance, intrahepatic lymphocytes, bariatric surgery, liver inflammation
- MeSH terms
- Adult, Animals, Cells, Cultured, Female, Humans, Interferon-gamma, Liver, Male, Middle Aged, Prospective Studies, Interleukin-4, Th2 Cells, Disease Progression, Lymphocyte Count, Interleukin-17, Bariatric Surgery, T-Lymphocytes, Regulatory, Mice, Th17 Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.